Home >> Signaling Pathways >> Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Products for  Immunology/Inflammation

  1. Cat.No. 产品名称 Information
  2. GC73808 Glutor Glutor是一种选择性GLUT 1/2/3抑制剂,可以抑制葡萄糖摄取。
  3. GC73796 CVN293 CVN293是一种选择性和脑渗透性钾离子(K+)通道KCNK13抑制剂,对hKCNK13和mKCNK13的ic50分别为41 nM和28 nM。
  4. GC73795 T-1-PMPA T-1-PMPA是一种具有凋亡特性的强效EGFR抑制剂。
  5. GC73794 PSMA binder-2 PSMA binder-2是PSMA的配体,可用于合成Ac-PSMA-trillium。
  6. GC73793 PSMA binder-1 PSMA binder-1是PSMA的配体,可用于合成Ac-PSMA-trillium。
  7. GC73786 ARV-393 ARV-393是一种口服活性PROTAC,利用泛素-蛋白酶体系统靶向BCL6的降解。
  8. GC73774 YCH2823 YCH2823是USP7的抑制剂(IC50 = 49.6 nM;Kd = 0.117 μM)。
  9. GC73773 PLK1/BRD4-IN-5 PLK1/BRD4-IN-5(化合物SC10)是一种口服活性PLK1和BRD4抑制剂,IC50值分别为0.3 nM和60.8 nM。
  10. GC73767 PKM2-IN-6 PKM2-IN-6(化合物7d)是一种强效的口服活性PKM2抑制剂,IC50值为23nM。
  11. GC73760 Trilexium

    TRX-E-009-1

    Trilexium (TRX-E-009-1)是与TRX-E-002-1结构相关的第三代苯并吡喃。
  12. GC73750 GLPG3312 GLPG3312(化合物28)是一种选择性泛sik抑制剂,对SIK1、SIK2和SIK3的IC50值分别为2.0 nM、0.7 nM和0.6 nM。
  13. GC73744 JAB-2485 JAB-2485是一种有效的选择性极光激酶a (AURKA)抑制剂,IC50为0.33 nM。
  14. GC73740 DCZ5418 DCZ5418是TRIP13的抑制剂。
  15. GC73730 RL-6-Me-7-OH RL-6-Me-7-OH是一种激活人和小鼠MAIT细胞的半抗原(EC50=25µM)。
  16. GC73702 NSC 689534 NSC 689534可与Cu2+形成铜螯合物。
  17. GC73697 STM3006 STM3006是一种高效、选择性和口服活性的METTL3抑制剂(IC50:5nM)。
  18. GC73688 Hydroxy-PP-Me Hydroxy-PP-Me是一种强效且特异的CBR1抑制剂,IC50为759nM。droxy PP-Me抑制血清戒断诱导的细胞凋亡。
  19. GC73678 RMC-4998 RMC-4998是一种口服活性抑制剂,靶向KRASG12C突变体的活性或gtp结合状态。
  20. GC73647 STING-IN-7 STING-IN-7(化合物21)是一种有效的STING抑制剂,IC50为11.5nM。
  21. GC73644 NT-0796 NT-0796是一种口服活性、选择性和中枢神经系统渗透性NLRP3炎性小体抑制剂。
  22. GC73643 NBI-961 NBI-961是一种有效的NEK2抑制剂,可抑制蛋白酶体降解。
  23. GC73634 Cu(II)-Elesclomol Cu(II)-Elesclomol是埃司克洛莫尔的Cu2+络合物。
  24. GC73632 NSC 48160 NSC 48160抑制癌症细胞的生长,CPFAC-1和BxPC-3的IC50分别为84.3μM和94.5μM。
  25. GC73631 FPR1 antagonist 1 FPR1 antagonist 1(化合物24a)是甲酰肽受体1(FPR1)拮抗剂,IC50为25nM。
  26. GC73630 ZZM-1220 ZZM-1220是一种组蛋白赖氨酸金属转移酶G9a/GLP共价抑制剂,IC50分别为458 nM和924 nM。
  27. GC73629 FB49 FB49是一种高选择性的bcl -2相关的无氧基因3 (BAG3)抑制剂,Ki为45 μM。
  28. GC73627 HDAC/JAK/BRD4-IN-1 HDAC/JAK/BRD4-IN-1(化合物25ap)是一种强效的HDAC/JAK/BRD4三重抑制剂。
  29. GC73601 UCM-1336 UCM-1336是一种有效的ICMT抑制剂,IC50为2μM。
  30. GC73599 TH9619 TH9619是MTHFD1和MTHFD2中去磷酸根酶和环磷酸根酶活性的有效抑制剂,IC50值为47nM,并选择性杀死癌症细胞。
  31. GC73594 KH16 KH16是一种有效的低纳摩尔HDAC抑制剂。
  32. GC73579 DDO-2728 DDO-2728(化合物19)是一种选择性AlkB同源物5(ALKBH5)抑制剂,IC50为2.97μM。
  33. GC73576 Enpp-1-IN-19 Enpp-1-IN-19(化合物29f)是一种口服活性的ENPP1抑制剂,可抑制ENPP1对cGAMP的水解(IC50=68 nM)。
  34. GC73572 PP5-IN-1 PP5-IN-1(化合物P053)是一种丝氨酸/苏氨酸蛋白磷酸酶-5 (PP5)的竞争性抑制剂,结合其催化结构域并导致肾癌细胞凋亡。
  35. GC73571 Tubulin polymerization-IN-56 Tubulin polymerization-IN-56吲唑衍生物是一种强效的微管蛋白聚合抑制剂,通过与秋水仙素位点相互作用,导致细胞周期阻滞和细胞凋亡。
  36. GC73569 MY-1076 MY-1076是YAP的抑制剂。
  37. GC73567 Os30 Os30是一种强效的第四代EGFR抑制剂,是一种有效的EGFRC797S-TK抑制剂,对EGFRDel19/T790M/C797S TK和EGFRL858R/T790M/C797S TK的IC50值分别为18 nM和113 nM。
  38. GC73561 YS-363 YS-363是一种强效、选择性和口服活性的EGFR抑制剂,野生型和L858R突变型EGFR的IC50分别为0.96 nM和0.67 nM。
  39. GC73555 PI3Kδ-IN-16 PI3Kδ-IN-16是PI3Kδ的强效选择性抑制剂。
  40. GC73552 TIM-3-IN-2 TIM-3-IN-2(化合物A-41)是一种Tim3抑制剂(KD:0.61μM)。
  41. GC73543 FC-116 FC-116是一种有效抑制小鼠肿瘤生长的微管蛋白抑制剂。
  42. GC73541 PRMT5-IN-31 PRMT5-IN-31(化合物3m)是一种选择性PRMT5抑制剂(IC50: 0.31 μM)。
  43. GC73501 Wu-5 Wu-5是一种USP10抑制剂,可以抑制FLT3和AMPK通路,诱导FLT3-ITD降解并诱导细胞凋亡。
  44. GC73496 ODN INH 18 sodium ODN INH 18 sodium是一种线性24-mer B类INH-ODN,其中5'INH-ODN4084-F序列后面是12个核苷酸的随机片段,缺乏形成重要二级结构的能力。
  45. GC73494 MSU-42011 MSU-42011是一种口服活性类视黄醇X受体(RXR)激动剂。
  46. GC73491 RapaBlock

    ZZY05-092

    RapaBlock是一种强效、非免疫抑制和脑不可渗透的FKBP12配体。
  47. GC73476 MYC-RIBOTAC MYC-RIBOTAC是一个靶向MYC内部核糖体进入位点(IRES)的核糖核酸酶嵌合体(RIBOTAC)。
  48. GC73469 Cereblon inhibitor 2 Cereblon inhibitor 2(化合物8)是一种Cereblon抑制剂,在实体肿瘤研究中非常有用,尤其是乳腺癌。
  49. GC73452 CCT374705 CCT374705是一种口服活性BCL6抑制剂,在体外具有强效的抗增殖作用。
  50. GC73441 EAPB 02303 EAPB 02303是一种微管破坏剂和抑制剂。
  51. GC73428 CWI1-2 hydrochloride CWI1-2 hydrochloride是一种结合IGF2BP2并抑制其与m6A修饰的靶转录物相互作用、诱导凋亡和分化的IGF2BP2抑制剂。

Items 151 to 200 of 4267 total

per page
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6

Set Descending Direction